ACE and COVID-19: Evidence on combined angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapy is limited, and the potential interaction with acid-base status has not been sufficiently explored.<h4>Methods</h4>We conducted a retrospective cohort study including adults with PCR-confirmed COVID-19 admitted to the intensive care unit (ICU) at Hospital Dr. Gustavo Fricke (Chile) between March 2020 and December 2021.